What are the biggest challenges and opportunities facing the life sciences sector? How can we overcome these challenges while unlocking the opportunities? Join host Stuart Lowe and a roster of expert guests as they unpack the past, present and future of cell and gene therapy.
In Season 3 of Invent: Life Sciences, we explored the forces redefining how tomorrow’s therapies will be developed, made, and delivered. From the challenges of scaling cell and gene therapy manufacturing to the transformative power of sustainability and AI, this season uncovered what it truly takes to move from discovery to delivery.
Featuring insights from leaders across Novartis, Cellular Origins, Orchard Therapeutics, Charles River, Cytiva, OmniaBio, Eli Lilly, and more, this season revealed how the biotech industry must evolve to make breakthrough therapies accessible, affordable, and ready for global deployment.
22 Sept 2025
Make Way for Advanced Therapies – Why Manufacturing Could be Coming to a Hospital Near You
In our last episode, we explored the manufacturing strategies that will be key to scaling advanced therapies. Now, we turn our focus to the UK, where new regulatory frameworks and regional collaboration are changing how therapies reach patients.
Stuart speaks with leading experts about the evolution of regulation, the role of the MHRA, and why decentralized manufacturing could unlock faster, more flexible access to treatments. He also hears how Cambridge is preparing to become a regional hub for manufacturing, and what this shift could mean for patients across the East of England and beyond. Together, these perspectives reveal how regulation, clinical insight, and patient needs are converging to shape the next chapter of cell and gene therapy in the UK.
Guests:
Jacqueline Barry (linkedin.com/in/jacqueline-barry-atmp), Chief Clinical Officer, Cell and Gene Therapy Catapult
Sarah Albon (https://www.linkedin.com/in/sarah-j-albon-91965858/), Director, Cambridge Cellular Therapy Laboratory at Cambridge University Hospitals NHS Foundation Trust
15 Sept 2025
Automation, Access, and the Future of Manufacturing
Manufacturing can make or break the future of cell and gene therapy. In this episode, Stuart sits down with two expert guests to share how smart design, automation, and closed systems are helping to lower costs, reduce complexity, and make therapies more accessible. From scaling strategies to operator-friendly technology, they reveal why manufacturing isn’t just a back-end process, but a critical part of therapy development from day one.
Guests:
Professor Mark Lowdell, CSO InMune Bio Inc (https://www.linkedin.com/in/mark-lowdell-3b98a129/?originalSubdomain=uk)
Luc Henry, Founder and CEO at Limula (https://www.linkedin.com/in/luc-henry/)
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
4.5 / 5
2 ratings
Spotify
5.0 / 5
5 ratings
Podcast Authority Score: 40 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
67
Social presence
0
YouTube
0
Engagement
32
Contact Invent: Life Sciences
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Invent: Life Sciences?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
